UNIGE document Scientific Article
previous document  unige:46872  next document
add to browser collection

European experience of docetaxel and cisplatin in advanced gastric cancer

Published in Gastric Cancer. 2002, vol. 5 Suppl 1, p. 27-9
Abstract The combination of docetaxel with cisplatin in gastric cancer is a promising development. In a phase II study, 85-100 mg/m2 docetaxel plus 75 mg/m2 cisplatin was established as an active regimen in advanced gastric cancer (with an overall response rate of 56%) with a manageable safety profile. Up to 300 mg/m2 5-fluorouracil (5-FU) given by continuous infusion for 2 of 3 weeks can be added to this regimen without an increase in appreciable toxicity. The efficacy of docetaxel-based regimens remains to be established by a randomized phase III study. However, the results of such trials are eagerly awaited, as are data from studies of docetaxel-based combinations in the adjuvant and neoadjuvant settings.
Keywords AdultAgedAntineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic useCisplatin/administration & dosageDisease ProgressionDisease-Free SurvivalFemaleFluorouracil/administration & dosageHumansMaleMiddle AgedPaclitaxel/administration & dosage/analogs & derivativesStomach Neoplasms/drug therapy/pathologyTaxoids
PMID: 12772884
Full text
Article (Published version) (128 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research group Groupe Roth Arnaud (oncologie) (285)
(ISO format)
ROTH, Arnaud. European experience of docetaxel and cisplatin in advanced gastric cancer. In: Gastric Cancer, 2002, vol. 5 Suppl 1, p. 27-9. doi: 10.1007/s10120-002-0204-5 https://archive-ouverte.unige.ch/unige:46872

309 hits

0 download


Deposited on : 2015-02-19

Export document
Format :
Citation style :